4 Things to Know about Type 1 Diabetes
Type 1 diabetes is an autoimmune disease that affects more than 2 million Americans.
- Type 1 diabetes is an autoimmune disease. In type 1 diabetes, the pancreas does not make insulin. In 1974, two studies published here and here in The Lancet highlighted research that showed how type-1 diabetes is associated with the development of antibodies directed against insulin-producing beta cells in the pancreas.
- Type 1 diabetes has three stages: stage 1, where patients are presymptomatic with normal blood glucose levels; stage 2, where patients are presymptomatic but have developed glucose intolerance; and stage 3, where patients develop symptoms that include increased hunger and thirst, blurry vision, fatigue, and diabetic ketoacidosis, a complication in which acids build up in the blood.
- In 2021, 38.4 million Americans had diabetes. Of these, 2 million had type 1 diabetes, including about 304,000 children, according to the CDC. About 1.7 million adults aged 20 years and older reported having type 1 diabetes and are using insulin. Between 2002 and 2018, the overall incidence of type 1 diabetes increased significantly. Non-Hispanic Asian or Pacific Islander children and adolescents has the largest significant increases in incidence of type 1 diabetes but non-Hispanic White children and adolescents had the highest overall incidence of type diabetes
- A large retrospective study published in the Journal of Managed Care & Specialty Pharmacy in 2020 of pediatric and adult patients with type 1 diabetes showed that overall medical costs averaged about $1,500 per patient per month, and diabetes-related costs totaled almost $800 per patient per month. Pharmacy costs contributed to more than half of the monthly diabetes related costs.
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
The Benefits of 'Hands-on' Coaching for Type 1 Diabetes
March 4th 2025In this part 2 video series, Arti Masturzo, M.D., chief medical officer of CCS, shares how coaching those with type 1 diabetes can deliver both measurable health improvements such as significant reductions in A1C levels, and enhanced patient confidence by providing hands-on education and support. Masturzo also addressed how CCS collaborates with healthcare providers and insurers to integrate care, reduce fragmentation and improve adherence to monitoring and treatment through AI-driven efforts.
Read More
